---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-150889"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T13:38:12.270541+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics reports Q1 net loss of $9.8M; first patient dosed in TCR-T Library trial

## Summary
- Net loss $9.8M ($0.05/sh) vs $21.6M ($0.10) in Q1 2021; cash $68.3M.
- First patient dosed in TCR-T Library Phase 1/2 trial targeting KRAS, TP53, EGFR mutations across six solid tumors.
- R&D expenses $5.6M (-58%), G&A $3.5M (-57%), operating cash burn $7.8M (-49%).
- Preclinical data on mbIL-15 presented at ASGCT; IND expected H2 2023.
- Initial clinical data expected H2 2022; cash runway into Q2 2023.

## SEC filing metadata
- accession: 0001193125-22-150889
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312522150889/0001193125-22-150889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312522150889/d359627d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-150889
- JSON: https://secwatch.observer/filing/0001193125-22-150889.json
- Plain text: https://secwatch.observer/filing/0001193125-22-150889.txt

## Key facts
- Earnings Releases
  Alaunos Therapeutics, Inc. reported three months ended March 31, 2022 results: net income Net loss was $9.8 million, or $(0.05) per share, EPS $(0.05) per share.
  - Period: three months ended March 31, 2022
  - Net income: Net loss was $9.8 million, or $(0.05) per share
  - EPS: $(0.05) per share
  - Result: reported results
  source text: Alaunos Therapeutics, Inc. issued a press release announcing its financial condition and results of operations for the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312522150889/0001193125-22-150889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.